Description
Anti-Interleukin 22 Antibody, Non-Fucosylated (BioBet-1082ZP) is a human monoclonal IgG antibody against Interleukin 22. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Inflammatory Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Interleukin 22 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL22
Full Name
interleukin 22
Alternative Names
IL22; interleukin 22; TIFa; IL-21; IL-22; ILTIF; IL-TIF; IL-D110; zcyto18; TIFIL-23; interleukin-22; cytokine Zcyto18; IL-10-related T-cell-derived inducible factor; IL-10-related T-cell-derived-inducible factor
Gene ID
50616
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL22 include Scleritis and Intestinal Tuberculosis.
Related Pathways
Its related pathways are PEDF Induced Signaling and Th17 cell differentiation.
Function
Cytokine that contributes to the inflammatory response in vivo.
Field of research
Immune System antibody; Signaling Transduction antibody
Post-translational modifications
1.Glycosylation at Asn54, Asn68, and Asn97 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1082ZP
Description
IL-22 is a recently described cytokine showing 23% amino acid identity with IL-10, and which has been previously shown to induce the production of acute phase proteins in liver and pancreas, suggesting a role in inflammatory responses. This antibody that binds to IL-22 is useful as modulators of a large panel of inflammatory disorders, including autoimmune diseases, cancer and sepsis. More particularly, anti-IL-22 antibody are reported to inhibit arthritis in a mouse model.
Antibody Indication
Inflammatory Diseases
